Activity

Global Indemnity Declares Distribution as Insurance Units Expand WILMINGTON, DE — Global Indemnity Group LLC (NASDAQ: GBLI) will distribute $0.35 per common share to shareholders later this month, returning capital t […]

Five Below Raises Outlook After Sales Surge Fuels Earnings PHILADELPHIA, PA — Five Below Inc. (NASDAQ: FIVE) raised its full-year sales and earnings outlook after reporting a sharp increase in first-quarter r […]

Vishay Targets EV Efficiency With New Power Module MALVERN, PA — Vishay Intertechnology Inc. (NYSE: VSH) has introduced a new power module aimed at reducing space requirements and improving power e […]

pharosIQ Launches Data Platform as AI Reshapes B2B Sales PHILADELPHIA, PA — pharosIQ has launched a new data-as-a-service offering aimed at helping businesses track buyer activity as artificial intelligence i […]

NextGen Pathology Adopts AI Platform to Expand Services PHILADELPHIA, PA — NextGen Pathology has selected Proscia’s Concentriq digital pathology platform as part of a strategy to expand subspecialty d […]

ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its S […]

Madrigal Investors Focus on Rezdiffra Growth at Goldman Event CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is set to present at the Goldman Sachs Global Healthcare Conference this week as i […]

Palvella Advances Rare Disease Drug Toward FDA Filing WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its l […]

Cabaletta Expands Autoimmune Strategy on Mid-Stage Data PHILADELPHIA, PA — Cabaletta Bio (Nasdaq: CABA) reported new clinical data suggesting its lead CAR-T cell therapy candidate could support regulatory f […]

Mineralys Restructures Drug Economics With $500 Million Financing RADNOR, PA — Mineralys Therapeutics (NASDAQ: MLYS) has agreed to eliminate future royalty obligations tied to its lead drug candidate lorundrostat w […]

Neuronetics Names Sales Chief, Grants Equity Incentive MALVERN, PA — Neuronetics Inc. (NASDAQ: STIM) has appointed healthcare sales executive Robert Greene as senior vice president of sales and awarded h […]

Orchestra BioMed Grants Equity Awards to New Employees NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) has granted stock options covering 85,500 shares to five newly hired employees, using an i […]

Callan Expands Advisory Services With Philanthropy Hire PHILADELPHIA, PA — Callan Family Office has hired philanthropic strategist George Burnette as director of philanthropic consulting and wealth, e […]

Obesity Survey Finds Gap Between Treatment Support and Use RADNOR, PA — New research comparing the views of primary care physicians and patients with obesity found broad acceptance of anti-obesity medications b […]

DOE Directs $500 Million Toward Coal Plants, Export Hub WASHINGTON, D.C. — The U.S. Department of Energy plans to provide up to $500 million in Defense Production Act funding to support 13 coal-related p […]

Angeion Names New CEO as Growth Strategy Enters Next Phase PHILADELPHIA, PA — Angeion Group has appointed veteran legal information executive Bill Carter as chief executive officer, a leadership change that s […]

Diversity Lab Shuts Down Amid FTC Antitrust Investigation WASHINGTON, D.C. — Diversity Lab LLC, a diversity, equity and inclusion consulting firm whose Mansfield Certification program was adopted by hundreds o […]

Palvella Set for Goldman Conference Amid Rare Disease Push WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) will present its development strategy to investors this week as the clinical-stage biotechnology c […]

Antares Reactor Milestone Advances U.S. Nuclear Deployment WASHINGTON, D.C. — Antares Nuclear has completed a fueled criticality demonstration of its Mark-0 microreactor at Idaho National Laboratory, a m […]

SEED Advances Cancer Drug Into Human Trials, Targets Hard-to-Treat Tumors KING OF PRUSSIA, PA — SEED Therapeutics has advanced its lead cancer drug candidate, ST-01156, into a first-in-human clinical trial, a step that will t […]